MEDS Lab

MEDS (Molecular Engineering & Drug Synthesis) is a South Korean biotechnology company specializing in the development of targeted protein degradation (TPD) therapeutics. The company leverages its proprietary AI-driven platforms, M-Glue and M-PROTAC, to discover and optimize novel molecular glues and PROTACs for challenging therapeutic targets. Their primary focus is on oncology, with lead programs targeting the androgen receptor variant AR-V7 for treatment-resistant prostate cancer and KRAS mutations for various solid tumors. By utilizing the body's natural protein disposal system, MEDS aims to create highly selective degraders that can overcome the limitations of traditional small molecule inhibitors. The company is headquartered in Suwon, South Korea, and is backed by several prominent venture capital firms.